Optimizing efficacy of Amphotericin B through nanomodification. - Wikidata - wikimedia - TriplyDB

Optimizing efficacy of Amphotericin B through nanomodification.

Optimizing efficacy of Amphotericin B through nanomodification.

http://www.wikidata.org/entity/Q37178176

about

Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer Liposomal resiquimod for the treatment of Leishmania donovani infection.Targeting Hypoxia Inducible Factors-1α As a Novel Therapy in Fibrosis Biodistribution and In Vivo Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl-sn-Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.

P2860

Q33947926-9311B6DC-FA0F-40A9-8B1D-2220D6711920 Q35168703-0D64FE1C-6372-487D-88D6-2119258D73F5 Q36951503-99E4C1D8-805F-4887-A77D-1E901500B14F Q37388288-C64B1B58-9AAE-4406-BE06-F1C513BFEF7E Q39370856-ACCC22E3-F7C6-41A4-89DB-596229D7B407 Q40166247-EE7AAEED-E4AA-4532-A093-F77C398BBF7F Q41703512-9C15F70B-C66C-4E73-A8D9-34EA3F768A70

P2860

Optimizing efficacy of Amphotericin B through nanomodification.

http://www.wikidata.org/entity/Q37178176

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimizing efficacy of Amphotericin B through nanomodification.

@en

Optimizing efficacy of Amphotericin B through nanomodification.

@nl

type

label

Optimizing efficacy of Amphotericin B through nanomodification.

@en

Optimizing efficacy of Amphotericin B through nanomodification.

@nl

prefLabel

Optimizing efficacy of Amphotericin B through nanomodification.

@en

Optimizing efficacy of Amphotericin B through nanomodification.

@nl

P1433

Q37178176-CD0985D7-D025-4416-80CB-479838E2B632

P1476

Q37178176-82BB01BC-E308-43F7-9325-902C00DBFF80

P2093

Q37178176-2E1C85CF-6B25-4F2E-8A07-C54749CEA61F

P2860

Q37178176-07D5FD27-48A7-47BF-BAAE-951A7DFF194A

Q37178176-09034702-C895-4276-85D9-EA06FC9D728C

Q37178176-0C40ECF8-49A2-49AC-A933-39CA129B4C73

Q37178176-0D1064E6-4E5F-4F8B-B62D-AEAC0EF882D2

Q37178176-0EA576B8-B52A-4CCA-933B-B0EAEE3CC5F9

Q37178176-108EDD28-537D-42D4-8503-56C06A9EA1ED

Q37178176-11102D23-5883-482C-828E-BB92A125A749

Q37178176-12834FE6-75F9-42D2-9439-BEEE8BF0764C

Q37178176-12FC7A71-E6C5-4F74-8749-783F480FF615

Q37178176-162B0BA5-ABA2-4965-A0A5-9B4EF3227EA5

P304

Q37178176-ADDDE33B-EA3E-4635-82D6-F2BED39FABEF

P31

Q37178176-02B29C6D-079A-46AB-8C88-AE9173115ADD

Q37178176-3EE4AB89-84F9-460D-8E9C-022C018F47AA

P407

Q37178176-C98B9747-4DD8-4B37-9E26-DFDD699C49C9

P433

Q37178176-E31E3AA9-DB8B-4CC9-8553-52A8BB9AC95C

P478

Q37178176-12DB8054-4FBC-49E3-B5D2-F6516C3A4701

P50

Q37178176-851494C6-A2BB-40BB-887D-2609CD0DFE5D

P577

Q37178176-68920060-CBF7-4507-AF79-7DC75BBC6EFF

P698

Q37178176-42AADF5B-4C1E-4773-8FAE-9D026AD832AB

P921

Q37178176-3DABD192-46C3-4EC3-96DB-4177BE0E8A68

Q37178176-631DD896-CB22-483C-9A77-D9AF96772DF1

Q37178176-77F63F7D-7BB5-4354-A826-D27D183EEC85

Q37178176-AB530F59-5937-4661-A835-C0714DBD965A

P932

Q37178176-E4CF7CB0-9F18-4337-9772-7F3AD102A748

P1433

International Journal of Nanomedicine

P1476

Optimizing efficacy of Amphotericin B through nanomodification

@en

P2093

Gillian Barratt

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes

Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice.

The study on brain targeting of the amphotericin B liposomes.

SolEmuls-novel technology for the formulation of i.v. emulsions with poorly soluble drugs.

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.

Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.

The past, present and future of antimycotic combination therapy.

Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures.

Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery.

P304

301-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Bretagne

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18019830

http://www.w3.org/2001/XMLSchema#string

P921

manufactured product

fungal infectious disease

pharmaceutical preparation

P932

2676657

http://www.w3.org/2001/XMLSchema#string